Abeona Therapeutics Inc.ABEONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank87
3Y CAGR+60.8%
5Y CAGR+29.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+60.8%/yr
Quarterly compound
5Y CAGR
+29.9%/yr
Recent acceleration
Percentile
P87
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 59.20% |
| Q3 2025 | -29.06% |
| Q2 2025 | -40.22% |
| Q1 2025 | 10.53% |
| Q4 2024 | 0.59% |
| Q3 2024 | -3.00% |
| Q2 2024 | 27.90% |
| Q1 2024 | -2.33% |
| Q4 2023 | 3.23% |
| Q3 2023 | -16.13% |
| Q2 2023 | 5.99% |
| Q1 2023 | 28.20% |
| Q4 2022 | 14.24% |
| Q3 2022 | -17.54% |
| Q2 2022 | -44.19% |
| Q1 2022 | -7.04% |
| Q4 2021 | 41.70% |
| Q3 2021 | 6.13% |
| Q2 2021 | 2.60% |
| Q1 2021 | -10.02% |
| Q4 2020 | 15.99% |
| Q3 2020 | 30.45% |
| Q2 2020 | -84.63% |
| Q1 2020 | 265.40% |
| Q4 2019 | -0.39% |
| Q3 2019 | -33.05% |
| Q2 2019 | 38.94% |
| Q1 2019 | 12.75% |
| Q4 2018 | -20.84% |
| Q3 2018 | 66.12% |
| Q2 2018 | -3.01% |
| Q1 2018 | 43.04% |
| Q4 2017 | 74.12% |
| Q3 2017 | -43.58% |
| Q2 2017 | 164.24% |
| Q1 2017 | -27.63% |
| Q4 2016 | 10.64% |
| Q3 2016 | -9.05% |
| Q2 2016 | 62.70% |
| Q1 2016 | -16.33% |